Under construction – not a live service
Sign in
Enrolling by invitationNo phase

An Observational Study of Patients With Chronic Liver Disease

Key facts

Who runs it
Target PharmaSolutions, Inc.
Where
Charlotte, Chicago, Dallas, Houston, Los Angeles, New York, Philadelphia, Redwood City, and Washington D.C., United StatesSee the 10 sites
Trial code
Status
Enrolling by invitation
People taking part
500,000 people, planned
Started
19 Feb 2024
Expected to end
31 Dec 2037
Type of study
Observational, 2 groups
Treatments tested
  • Observational
Record updated
3 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Disease Cohort
  • •Adult* patients at the time of enrollment with a diagnosis of CLD/cirrhosis by ICD-10 code in the EHR interface
  • Engaged Cohort
  • Adult* patients diagnosed and managed for CLD/cirrhosis invited to participate
  • Ability to provide written informed consent

Who cannot take part

  • Disease Cohort
  • Failure to complete PROs within 24 weeks of initial invitation
  • Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort
  • No EHR interface encounter > 3 years; Engaged Cohort
  • Death
  • Manual removal (sponsor or site request)
  • Patient expressed desire to withdraw consent to complete PROs
  • Greater than 24 months lapse of survey completion after baseline surveys completed

Where in United States

  • Atrium Health Center for Liver Disease and TransplantCharlotte, United StatesNo longer taking part
  • Rush University Medical CenterChicago, United StatesNo longer taking part
  • Baylor Scott & White Research InstituteDallas, United StatesNo longer taking part
  • Baylor College of MedicineHouston, United StatesNo longer taking part
  • Keck School of Medicine of USCLos Angeles, United StatesNo longer taking part
  • Columbia University Irving Medical Center/New York Presbyterian HospitalNew York, United StatesNo longer taking part
  • Temple University Lewis Katz School of MedicinePhiladelphia, United StatesNo longer taking part
  • University of PennsylvaniaPhiladelphia, United StatesNo longer taking part
  • Stanford MedicineRedwood City, United StatesNo longer taking part
  • Georgetown Medstar Transplant InstituteWashington D.C., United StatesNo longer taking part

About the trial

What the trial wants to find out

TARGET-Liver Disease (TARGET-LD) is an observational research study to conduct a comprehensive review of outcomes for patients with chronic liver disease (CLD).

The 2 groups in the trial

  • Disease Cohort

    Treatment: Observational

  • Engaged Cohort

    Treatment: Observational

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
3 March 2026